Journal of Developmental Medicine(Electronic Version) 2015, Vol. 3 Issue (3): 156-159 DOI: |
|
|
|
|
|
|
The evaluation of cyclophosphamide combined with prednisone in infant nephrotic syndrome |
YU Zhi-qi,JIANG Luo,YU Sheng-you,YU Li
|
YU Zhi-qi,JIANG Luo,YU Sheng-you,YU Li(Department of Pediatrics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China) |
|
|
Abstract Objective To investigate the clinical efficacy of cyclophosphamide combined with prednisone on treating nephrotic syndrome(NS) in infant. Method From January 2010 to December 2014 in our hospital, 61 children with nephrotic syndrome were analyzed retrospectively. The treatment group (29 cases) received the treatment of cyclophosphamide and prednisone, while the control group (32 cases) only received the treatment of prednisone. The biochemical indicators were counted and analysised before treatment and 6 months, including the 24h urinary protein excretion and others. Also, we need to observe adverse reactions. Results Compared with the control group, the treatment group has the lower 24h urinary protein and other biochemical indicators after 6 months. There was significant difference between the two groups(P<0.05). In the treatment group, complete remission was achieved in 18 cases,partial remission in 4cases.The effective
rate was 76%. While, the control group induced 9 cases complete remission, partial remission in 6 cases. The effective rate was 47%. There was significant difference in the effective rate between the two groups(P<0.05). The occurrence rate of infectious diseases in the treatment group was obviously lower than the control group, but the incidence rate of gastrointestina reactions was higher. There was significant difference between them (P<0.05). Conclusions Cyclophosphamide and prednisone combination therapy has a higher remission rate and lower infectious rate than only the treatment of prednisone. So, it is worth to be popularized and applied in clinical treatment
|
Received: 11 February 2015
Published: 14 May 2018
|
|
|
|
|
|